Organon Is Ready To Launch And Makes The Case To Investors
Established Products Will Account For The Majority Of Revenues
Executive Summary
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
You may also be interested in...
BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?
News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.
BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?
News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.
How Organon Expects To Steer Its Women’s Health Engine In India
Organon commercial director and lead for the South Asia Region, Anjan Sen, lays out how the Merck spin-out expects to scale up activities in markets like India. A mix of new products, targeted repurposing efforts and access-driven pricing are part of the strategy that could potentially see the company double its presence in the region.